Quantum Leap Healthcare

I-SPY 2, an Innovative Clinical Trial Model…

Presentation of advances from the groundbreaking…

Washington, D.C., – Quantum Leap Healthcare Collaborative™ (QLHC), a non-profit organization and sponsor of the I-SPY 2 TRIAL™, today presented an overall view of the remarkable progress achieved by the I-SPY 2 clinical trial in improving the outcomes of early stage, breast cancer patients who are at high risk for early recurrence. I-SPY 2 is also impacting far beyond breast cancer by increasing efficiencies that promise to accelerate the development and delivery of more effective therapies for other cancer types and a range of other diseases.

Open »